Deralin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deralin

Property Description
Active ingredient Propranolol hydrochloride
Form Tablet, Capsule, Solution (oral/IV)
Pharmacological class Beta-adrenergic blocking agent (β-blocker)
Common use Control of heart rate and pressure
Origin Synthetic compound

What Type of Medicine is Deralin?

Deralin is a synthetic prescription medicine whose active ingredient is the non-proprietary (INN) compound Propranolol hydrochloride. It belongs to the pharmacological class of beta-adrenergic blocking agents, or simply beta-blockers. This drug is widely recognized in clinical practice as one of the original and most frequently studied β-blockers.

This classification establishes Deralin as a first-generation agent, specifically a non-selective β-antagonist. This non-selectivity means the compound acts to block both β1 receptors (primarily in the heart) and β2 receptors (found in other tissues), a feature that historically distinguished it from later, more selective agents. This class of drug is designed to decrease the nerve impulses sent to the heart and blood vessels, confirming its long-standing role in cardiovascular regulation.

Composition and Available Forms of Deralin

Deralin is a single-ingredient product, containing only Propranolol hydrochloride as its medicinal component. While Propranolol is the INN, Deralin is one commercial preparation among others with the same formulation. The medication is available in several dosage form(s) for patient use, including conventional tablets, long-acting extended-release capsules, and an oral solution.

It is also prepared as a sterile solution for intravenous injection in acute settings. The availability of both immediate- and extended-release capsules is a key differentiating factor, enabling flexible treatment strategies, though the primary route of administration remains oral ingestion.

General Role and Purpose of Beta-Blockers

The fundamental purpose of Deralin is to exert control over the sympathetic nervous system's response to stress and stimulation. By blocking the effects of catecholamines like epinephrine, Deralin causes a reduction in the heart's pumping force and a lowering of the heart rate.

This inhibitory action is crucial for its overarching general benefit: reducing the heart’s workload and its oxygen demand, while simultaneously promoting stabilization of the cardiac rhythm. Propranolol's key action is reducing heart rate and cardiac output, meaning the drug works by helping the heart pump less intensely and more smoothly.

Regulatory References

  1. Beta Blockers (Beta-Adrenergic Blocking Agents)
  2. Mechanism of Action: Beta Blockers and Sympathetic Nervous System
  3. Propranolol Mechanism (NIH StatPearls)

What side effects are possible with Deralin?

Possible Side Effects and Safety Information

The safety profile of Deralin (Propranolol hydrochloride) is classified according to regulatory standards based on frequency and the body system affected. These classifications reflect how government regulatory documents organize and communicate the medicine’s safety profile.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their rate of occurrence as documented in official regulatory labels:

  • Common (may affect up to 1 in 10 people): Fatigue, general tiredness, bradycardia (slowed heart rate), cold extremities, and gastrointestinal disturbances such as nausea, vomiting, or diarrhea.
  • Uncommon (may affect up to 1 in 100 people): Hallucinations.
  • Rare (may affect up to 1 in 1,000 people): Dizziness, mood alteration, confusion, dry eyes, and bronchospasm (difficulty breathing), particularly in patients with pre-existing asthma.

Systemic Safety and Constraints

The documented adverse effects primarily involve the Cardiac, Nervous System, Psychiatric, and Respiratory system-organ classes. The official profile highlights certain conditions that represent high-level safety constraints for use:

  • Serious Adverse Reactions (SARs): The regulatory label documents the potential for serious reactions, including the worsening or precipitation of congestive heart failure, severe bradycardia, or severe bronchospasm.
  • Safety Constraints: Deralin is typically contraindicated in patients with conditions such as bronchial asthma, uncontrolled heart failure, severe bradycardia, or cardiogenic shock.
  • Population-Specific Notes: Caution is explicitly advised for patients with hepatic (liver) or renal (kidney) impairment due to reduced drug clearance, and for diabetic patients as the medication may mask symptoms of low blood sugar (hypoglycaemia).

The safety information structures the understanding of risks by categorizing both expected and severe reactions, ensuring that potential issues related to the drug's fundamental beta-blocking action are clearly disclosed.

Overdose and Emergency Response

Overdose and when to seek help

Suspected overdose of Deralin (Propranolol) is a condition documented in regulatory information as potentially life-threatening and requires immediate medical attention.


Documented Overdose Manifestations

Regulatory documents describe overdose presentations that primarily reflect severe physiological compromise. Clinical manifestations include severe bradycardia (slow heart rate) and profound hypotension, which can escalate to cardiac collapse or cardiac arrest. Other documented presentations involve the Central Nervous System, such as drowsiness, confusion, coma, and seizures. Overdose may also be associated with systemic hypoglycemia (low blood sugar), which is noted as a particularly common feature in pediatric cases.


Emergency Actions Required

Given the potential for a fatal outcome, regulatory guidance explicitly mandates that individuals must seek emergency medical help right away if an overdose is suspected. Delay in treatment increases the risk of serious consequences. Management, which must occur under medical supervision, is supportive and focuses on limiting further absorption with agents such as Activated charcoal, and treating severe instability with agents like Glucagon. Continuous monitoring of vital signs and cardiac function is required.

Therapeutic Uses of Deralin

What Deralin Treats: Main Uses and Benefits

The therapeutic applications of Deralin (Propranolol) are applied across domains where additional symptomatic support is needed. The medication is commonly used across conditions presenting with acute or episodic manifestations where short-term symptomatic assistance is needed. It helps ease the overall burden of symptoms and contributes to improved day-to-day comfort during periods of increased distress.

Symptom Relief Domains

Deralin is relevant when supportive symptom management is appropriate across areas including cardiac instability, neurological symptoms, and stress response management. It is relevant for easing symptoms that interfere with daily functioning across conditions such as high blood pressure, chronic chest pain (angina pectoris), certain irregular heart rhythms, essential tremor, and migraine headaches. This medication is applicable within clinical settings that involve acute or disruptive symptom patterns.

Managing Cardiac Instability: Deralin contributes to easing the overall symptom load for patients managing high blood pressure and in clinical settings that involve acute or unstable symptom patterns. It contributes to easing symptoms related to systemic imbalance such as palpitations and a rapid heart rate.

Reducing Tremor and Migraine: It may assist with reducing the intensity of essential tremor and is applied to minimize the frequency of disruptive migraine headaches.

Modulating Stress Responses: It is relevant for easing physical symptoms like trembling, sweating, and a racing heart associated with situational anxiety, contributing to improved comfort during difficult episodes.


Quick Fact: Supportive Relief for Symptoms Related to Tension

Deralin is relevant for easing symptoms that create noticeable physiological strain—like shaking or rapid heartbeat—and assists with maintaining functional stability by easing symptoms when they become more noticeable.

Regulatory References

  1. NIH MedlinePlus overview on Propranolol

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

The eligibility profile for Deralin (Propranolol) is strictly defined by official regulatory documentation. Absolute contraindications prohibit its use in patients with specific critical conditions where the drug's action poses a danger.

Populations That Must Not Use Deralin

  • Cardiovascular: Individuals with cardiogenic shock, sinus bradycardia, second- and third-degree heart block, or overt, uncontrolled heart failure.
  • Respiratory: Patients diagnosed with bronchial asthma or a history of bronchospasm.

Restricted or Conditional Use Populations

Use in several other populations is permitted but requires explicit caution or is restricted, as defined by the official label:

  • Organ Function: Patients with hepatic (liver) or renal (kidney) impairment must be monitored closely due to potential changes in drug clearance and increased systemic exposure.
  • Metabolic: Patients with diabetes or those prone to fasting require careful risk evaluation, as the drug can mask symptoms of acute hypoglycemia.
  • Age: Safety and efficacy are not established for most uses in children over one year of age.
  • Reproductive Status: For pregnant individuals, Deralin is classified as FDA Category C. Use is not recommended during lactation because the drug is excreted into human milk.

What should I know about interactions with other medicines?

Deralin (Propranolol) is a beta-blocker that can interact with many other medicines, increasing the risk of side effects or altering the effects of one or both drugs. Discuss all medications, supplements, and herbal products with a healthcare provider before starting Deralin.

Key Interacting Agents and Conditions

Product Class / Specific Medicine Interaction Effect and Concern
Calcium Channel Blockers (e.g., Verapamil, Diltiazem) May cause dangerously low heart rate, low blood pressure, or heart block. Extreme caution is required, and this combination is generally avoided.
Antiarrhythmic Drugs (e.g., Amiodarone, Quinidine, Digoxin) Risk of an excessively slow or irregular heartbeat (bradycardia), or hypotension, due to additive effects on the heart.
Diabetic Medicines (e.g., Insulin, blood glucose lowering agents) Deralin may mask warning signs of low blood sugar (hypoglycaemia), such as a fast heart rate, and may prolong the time needed to recover from low blood sugar.
Drugs affecting CYP enzymes Medicines that block the liver enzymes (CYP2D6, CYP1A2) that break down Deralin can increase Deralin's concentration in the blood, raising the risk of side effects.
General Anaesthetics Inform your doctor if you are planning surgery, as the combination may cause a sudden, severe drop in blood pressure.
Alcohol May increase the effects of Deralin, potentially worsening dizziness and light-headedness.

If you have a history of severe allergic reactions (anaphylaxis), be aware that Deralin may worsen the reaction and may reduce the effectiveness of injectable epinephrine (Adrenaline).

Mechanism of Action

Non-Selective Beta-Adrenergic Receptor Blockade

Deralin's core mechanism involves acting as a competitive antagonist to block both beta1 and beta2 adrenergic receptors found throughout the body. By occupying these receptor sites, Deralin prevents the stimulating effects of the stress hormones epinephrine and norepinephrine, which alters the subsequent signaling sequences in the pathway.


Modulating Cardiac and Vascular Dynamics

This blockade primarily affects the cardiovascular system by reducing the rate and force of heart contractions (due to beta1 receptor inhibition). It also engages the Renin-Angiotensin-Aldosterone System (RAAS) by suppressing renin release from the kidneys. The pathway adjustment contributes to a reduction in cardiac oxygen demand and facilitates changes in the activity of targeted pathways.


Reducing Sympathetic-Mediated Physiological Processes

The mechanism extends beyond the heart to diminish the overall activity of the sympathetic nervous system. The mechanistic interference with adrenergic signaling modulates the physical consequences of high-level nervous system activity. This reduction of sympathetic-mediated physiological processes leads to predictable adjustments that characterize the drug's overall mechanism.

Dosage and Administration Information

Deralin (Propranolol hydrochloride) is administered through two primary, approved routes of administration: the oral route for long-term and divided-dose regimens, and the intravenous (IV) route for acute, controlled clinical settings, such as certain arrhythmias.

Official Dosing and Administration Schedules

Official dosing is strictly dependent on the formulation. Immediate-Release (IR) tablets are typically taken in divided doses multiple times per day (e.g., two to four times daily), with a general maintenance range of 80 mg to 320 mg per day. In contrast, Extended-Release (ER) capsules are designed for once-daily administration. For some ER capsules, administration is specifically directed to occur at bedtime (around 10 PM).

  • Administration Conditions: Oral capsules, especially ER forms, must be swallowed whole and must not be crushed, chewed, or opened. Consistency with food intake is required; the medicine should be taken consistently either always with food or always on an empty stomach.
  • Acute and Special Use: IV administration is carried out slowly, generally not exceeding 1 mg per minute. For older adults, instructions for use specify that treatment should start with the lowest effective dose. Pediatric dosing for approved uses is determined weight-based and requires periodic readjustment as the child's weight changes.
  • Discontinuation Protocol: Deralin therapy must not be stopped abruptly. The dosage is withdrawn gradually over a period of at least a few weeks (e.g., 7 to 14 days) to maintain a controlled transition.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Deralin

This section summarizes the types of foundational research, primarily randomized controlled trials and large observational studies, that evaluated the compound’s use in conditions related to heart rate and blood pressure control.

Deralin (Propranolol) was studied for hypertension (high blood pressure) and angina pectoris (chronic chest pain) using randomized controlled trials (RCTs). In these trials, researchers primarily measured changes in systolic and diastolic blood pressure (SBP/DBP) and assessed patient-reported outcomes describing perceived discomfort such as exercise tolerance and the frequency of chest pain episodes. Large-scale, long-term observational studies were also observed in to track how the compound was associated with outcomes related to physiological strain and other major events over many years. Findings describe patterns observed in the studies where participants receiving the compound showed shifts in blood pressure readings and reported changes in the frequency of chest pain episodes.

Long-term research was also evaluated in studies of adults who survived a heart attack (Post-Myocardial Infarction). In these large cohort studies, researchers monitored major clinical endpoints, including outcomes related to physiological strain. Large-scale studies reported data show patterns related to long-term cardiovascular outcomes observed in the group receiving the study compound compared to the control group.

Studies of Blood Pressure and Angina Symptoms

While the existing research is robust and foundational, a key point of uncertainty is that many of the original RCTs are historical. This means there is a limited number of recent large-scale trials directly comparing Deralin against some modern, currently available first-line hypertension agents. Similarly, the evidence for angina typically focuses on short-term follow-up in controlled settings. Short-term trials reported measurements of changes in exercise time and described changes in the frequency of patient-reported episodes when the compound was administered versus placebo.


Evidence for Use in Neurological and Symptom Management

This section outlines the research landscape for Deralin's application in managing specific symptoms related to the nervous system, focusing on controlled clinical trials that examined essential tremor and the use of the compound for migraine prophylaxis.

For essential tremor, researchers used in research exploring how symptoms change over time to compare the compound to an inactive treatment. Studies primarily measured changes in tremor severity using standardized clinical rating scales and objective measurements of tremor amplitude. Studies reported changes measured during the study period, including shifts in tremor rating scale scores and changes in objective tremor amplitude in the group receiving the compound. However, these studies are often modest in sample sizes and focus on short-term changes (typically a few weeks), meaning there is limited information for long-term outcomes regarding the compound’s effect on functional activity level over many years.

Key Studies & References

  1. PROPRANOLOL HYDROCHLORIDE tablet - DailyMed (NIH)
  2. Long-Term Effect of β-Blocker Use on Clinical Outcomes in Postmyocardial Infarction Patients: A Systematic Review and Meta-Analysis (Post-MI evidence)

Frequently Asked Questions (FAQ)

Common questions about Deralin (FAQ)

Q: How quickly can someone expect Deralin to start working?

Official pharmacological data indicates that the active ingredient in Deralin, Propranolol, has a biological half-life of approximately 3 to 6 hours. This half-life is the time it takes for half of the drug to be eliminated from the body. While initial effects may begin shortly after administration, reaching the full, stable therapeutic benefit often requires continuous therapy over a longer period, sometimes assessed over several weeks.

Q: What happens if a dose of Deralin is missed?

Regulatory documents state that patients should not take two doses at the same time to compensate for a missed dose. The specific protocol for handling a missed dose depends entirely on the product formulation (e.g., immediate-release vs. extended-release). Patients should reference the specific protocol for a missed dose detailed in their official patient information leaflet.

Q: Is Deralin considered a safe medication for long-term use?

Deralin is approved and studied for the treatment of chronic conditions, such as hypertension, which often necessitate long-term, sustained therapy. Official safety instructions caution against stopping chronic treatment suddenly or abruptly, as this may be associated with serious cardiac risks, including the worsening of angina or a heart attack.

Q: How long does Deralin stay in your system after stopping?

According to official pharmacological data, the drug’s elimination half-life is typically between 3 to 6 hours, meaning half the drug is removed in that time frame. The total time it takes for the entire medication to be fully cleared from the system depends on individual biological factors and the specific Deralin formulation used.

Q: Can Deralin be taken with coffee or caffeine products?

Caffeine acts as a sympathomimetic, meaning it can oppose the heart rate and blood pressure lowering effects of beta-blockers like Deralin. Additionally, both Deralin and caffeine are processed by common liver enzymes (CYP1A2). Regulatory warnings suggest that changes in caffeine intake could potentially be associated with altered Deralin concentrations and effects in the body.

Q: Is Deralin habit-forming or addictive?

Deralin is not classified as a controlled substance and is not considered habit-forming in the typical sense of addiction. However, official regulatory labels highlight the risk of a severe reaction or withdrawal syndrome if the medication is stopped abruptly. Official information requires the dosage to be gradually reduced over a period of time, rather than stopping abruptly.

Q: Is it safe to drive or operate machinery while taking Deralin?

The official product label lists side effects like dizziness, fatigue, and confusion as potential adverse reactions. Regulatory information notes that because these effects may impair concentration, operating heavy machinery or driving may require caution, particularly during the initial phase of therapy.

Q: Does Deralin cause vivid dreams or sleep disturbances?

Sleep disturbance is a documented adverse reaction reported in regulatory documents associated with the use of propranolol. This is a recognized effect that patients may experience, although it is not considered one of the most common side effects.

Q: What kinds of tests or monitoring are needed while taking Deralin?

Official safety information advises that monitoring of heart rate and rhythm is generally recommended during Deralin therapy, particularly if other cardiac medicines are also being taken. Additional monitoring of liver or kidney function may be advised for patients with pre-existing organ impairment, due to potential changes in how the body processes the drug.

Q: Does Deralin interact with herbal medicines like St. John's Wort?

Regulatory documents warn that medicines and supplements that increase the rate at which the body processes Deralin can reduce its concentration in the blood, decreasing its effectiveness. St. John’s Wort is specifically known as an enzyme inducer that can accelerate the metabolism of Deralin.

Q: What is the typical time frame for the expected effects of Deralin?

While the drug begins to act relatively quickly due to its short half-life, the full therapeutic benefit for chronic conditions like hypertension is assessed over several weeks. Official studies define effectiveness by tracking continuous changes in blood pressure and heart-related symptoms during this sustained treatment period.

Q: Is Deralin known to cause dry mouth?

Although dry eyes are listed as a rare side effect in regulatory documents, dry mouth is not explicitly listed as a common or rare adverse reaction. However, the drug’s primary mechanism involves the autonomic nervous system, which is responsible for controlling salivation and other involuntary body functions.

Q: What is the purpose of the black box warning on Deralin?

The most prominent warning on the official U.S. label is the risk of a cardiovascular event, such as a heart attack, if the therapy is stopped suddenly. This regulatory caution is specifically directed at patients being treated for angina pectoris (chest pain) or other ischemic heart conditions, requiring the dose to be reduced gradually.

Q: What common supplements interact with Deralin?

Official interaction data focuses on substances that interfere with the CYP liver enzymes responsible for metabolizing Deralin. Supplements or vitamins that affect these enzymes or contain minerals can potentially alter Deralin’s concentration, raising the risk of either side effects or reduced effectiveness.

Q: Does Deralin have a known interaction with grapefruit juice?

Grapefruit juice is recognized as an inhibitor of certain CYP enzymes that help break down medicines. Official warnings indicate that inhibitors of these key enzymes can increase Deralin’s concentration in the bloodstream, potentially raising the risk of adverse reactions.

Q: Does taking Deralin impact birth control pills?

Regulatory documents describe a potential interaction with hormonal contraceptives. Estrogen-containing birth control pills may lead to higher levels of Deralin in the blood, which could result in a more pronounced reduction in heart rate or blood pressure.

Q: What is the official recommended use period for Deralin?

The drug is officially indicated for the management of chronic, long-term conditions like hypertension and angina. Therefore, regulatory documents do not define a specific time-limited use period; rather, the compound is intended for sustained therapy as long as clinical benefit is maintained.

Q: Are there any specific foods that must be avoided with Deralin?

The official label primarily warns against alcohol consumption due to the risk of increased dizziness and light-headedness. While consistency (always with food or always without) is required for administration, no specific food item is universally mandated for avoidance, outside of interactions like grapefruit juice.

How should Deralin be stored and disposed of?

How to Store and Dispose of Deralin (Propranolol Hydrochloride)

Official regulatory documents define specific storage and disposal requirements for Deralin to maintain its stability and ensure safety.

Required Storage Conditions

Deralin must be stored below 30 C in a cool, dry place, and should be protected from light and moisture. The medicine must be kept in its original container, and the container must be tightly closed. It is mandatory to keep from freezing and to store the product out of the sight and reach of children at all times.

Disposal Instructions

Any unused or expired Deralin product must be discarded in accordance with local requirements. Official guidelines state that disposal should avoid discharge into drains, water courses, or onto the ground to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deralin found in:

A-Z Index: